Weill research highlighted at #GU15 conference
Mark Rubin, M.D., Himisha Beltran, M.D., Bishoy Faltas, M.D., Manish Shah, M.D., Ana Molina, M.D., and Jim Hu, M.D., were among several Weill Cornell physician-scientists whose work was highlighted at the 2015 Genitourinary Cancers Symposium, held in Orlando on Feb. 26-28.
As part of a symposium on "Integrating Biology Into Patient-Centric Care," Dr. Rubin described advances and obstacles in prostate cancer biomarkers and their development. As reported in UroToday, he reviewed the EDRN approach to biomarker development, which is a formalized protocol using decision trees to determine when to take each marker to the next developmental stage and emphasizes reproducibility, and talked about the potential of precision medicine in this field.
Dr. Beltran and colleagues presented a poster about FANCA loss as a biomarker of platinum sensitivity in prostate cancer, also reported in UroToday. Their work suggested that although historically prostate cancer is not considered platinum-sensitive, a subset of these tumors might be amenable to therapy with cisplatin/docetaxel.
Dr. Shah shared the results of a multicenter study into inhibiting the MET pathway in gastroesophageal cancer. Read more about his findings in this report from the ASCO Post.
Dr. Molina shared her clinical expertise on the optimal treatment on high-risk localized prostate cancer, and new Meyer Cancer Center member Jim Hu discussed his research into the toll depression can take on those with prostate cancer.
Dr. Faltas, a clinical fellow, presented on clonal heterogeneity in platinum-resistant metastatic urothelial cancer, and spoke to Targeted Oncology about it in this video.
Read more about the conference here.
